Esophagitis, Eosinophilic, 1 (EOE1)

Categories: Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Esophagitis, Eosinophilic, 1

MalaCards integrated aliases for Esophagitis, Eosinophilic, 1:

Name: Esophagitis, Eosinophilic, 1 58 13
Eosinophilic Esophagitis 12 60 38 44 45 15 17 74
Esophagitis, Eosinophilic; Ee 58
Esophagitis, Eosinophilic 58
Eoe1 58
Eoe 60
Ee 58


Orphanet epidemiological data:

eosinophilic esophagitis
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-5/10000 (Canada),1-5/10000 (Japan),1-5/10000 (Spain),1-5/10000 (Europe),1-5/10000 (United States),1-9/100000 (Switzerland),1-5/10000 (Switzerland); Age of onset: All ages; Age of death: normal life expectancy;



predominantly occurs in young males with high rate of atopic disease


External Ids:

Disease Ontology 12 DOID:13922
OMIM 58 610247
KEGG 38 H01361
ICD9CM 36 530.13
MeSH 45 D057765
NCIt 51 C27105
ICD10 34 K20.0
MESH via Orphanet 46 D057765
ICD10 via Orphanet 35 K20
UMLS via Orphanet 75 C0341106
Orphanet 60 ORPHA73247
MedGen 43 C4551589
UMLS 74 C0341106

Summaries for Esophagitis, Eosinophilic, 1

MedlinePlus : 44 What is eosinophilic esophagitis (EoE)? Eosinophilic esophagitis (EoE) is a chronic disease of the esophagus. Your esophagus is the muscular tube that carries food and liquids from your mouth to the stomach. If you have EoE, white blood cells called eosinophils build up in your esophagus. This causes damage and inflammation, which can cause pain and may lead to trouble swallowing and food getting stuck in your throat. EoE is rare. But because it is a newly recognized disease, more people are now getting diagnosed with it. Some people who think that they have reflux (GERD) may actually have EoE. What causes eosinophilic esophagitis (EoE)? Researchers are not certain about the exact cause of EoE. They think that it is an immune system/allergic reaction to foods or to substances in your environment, such as dust mites, animal dander, pollen, and molds. Certain genes may also play a role in EoE. Who is at risk for eosinophilic esophagitis(EoE)? EoE can affect anyone, but it is more common in people who Are male Are Caucasian Have other allergic diseases, such as hay fever, eczema, asthma and food allergies Have family members with EoE What are the symptoms of eosinophilic esophagitis (EoE)? The most common symptoms of EoE can depend on your age. In infants and toddlers: Feeding problems Vomiting Poor weight gain and growth Reflux that does not get better with medicines In older children: Vomiting Abdominal pain Trouble swallowing, especially with solid foods Reflux that does not get better with medicines Poor appetite In adults: Trouble swallowing, especially with solid foods Food getting stuck in the esophagus Reflux that does not get better with medicines Heartburn Chest pain How is eosinophilic esophagitis (EoE) diagnosed? To diagnose EoE, your doctor will Ask about your symptoms and medical history. Since other conditions can have the same symptoms of EoE, it is important for your doctor to take a thorough history. Do an upper gastrointestinal (GI) endoscopy. An endoscope is a long, flexible tube with a light and camera at the end of it. Your doctor will run the endoscope down your esophagus and look at it. Some signs that you might have EoE include white spots, rings, narrowing, and inflammation in the esophagus. However, not everyone with EoE has those signs, and sometimes they can be signs of a different esophagus disorder. Do a biopsy. During the endoscopy, the doctor will take small tissue samples from your esophagus. The samples will be checked for a high number of eosinophils. This is the only way to make a diagnosis of EoE. Do other tests as needed. You may have blood tests to check for other conditions. If you do have EoE, you may have blood or other types of tests to check for specific allergies. What are the treatments for eosinophilic esophagitis (EoE)? There is no cure for EoE. Treatments can manage your symptoms and prevent further damage. The two main types of treatments are medicines and diet. Medicines used to treat EoE are Steroids, which can help control inflammation. These are usually topical steroids, which you swallow either from an inhaler or as a liquid. Sometimes doctors prescribe oral steroids (pills) to treat people who have serious swallowing problems or weight loss. Acid suppressors such as proton pump inhibitors (PPIs), which may help with reflux symptoms and decrease inflammation. Dietary changes for EoE include Elimination diet. If you are on an elimination diet, you stop eating and drinking certain foods and beverages for several weeks. If you are feeling better, you add the foods back to your diet one at a time. You have repeat endoscopies to see whether or not you are tolerating those foods. There are different types of elimination diets: With one type, you first have an allergy test. Then you stop eating and drinking the foods you are allergic to. For another type, you eliminate foods and drinks that commonly cause allergies, such as dairy products, egg, wheat, soy, peanuts, tree nuts and fish/shellfish. Elemental diet. With this diet, you stop eating and drinking all proteins. Instead, you drink an amino acid formula. Some people who do not like the taste of the formula use a feeding tube instead. If your symptoms and inflammation go away completely, you may be able to try adding foods back one at a time, to see whether you can tolerate them. Which treatment your health care provider suggests depends on different factors, including your age. Some people may use more than one kind of treatment. Researchers are still trying to understand EoE and how best to treat it. If your treatment is not working well enough and you have narrowing of the esophagus, you may need dilation. This is a procedure to stretch the esophagus. This makes it easier for you to swallow.

MalaCards based summary : Esophagitis, Eosinophilic, 1, also known as eosinophilic esophagitis, is related to peptic esophagitis and esophageal candidiasis, and has symptoms including vomiting and epigastric pain. An important gene associated with Esophagitis, Eosinophilic, 1 is BANCR (BRAF-Activated Non-Protein Coding RNA), and among its related pathways/superpathways are JAK-STAT signaling pathway (KEGG) and Immune response IFN gamma signaling pathway. The drugs Fluticasone and Budesonide have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and bone, and related phenotypes are dysphagia and edema

Disease Ontology : 12 An esophagitis characterized by inflammation involving eosinophils located in esophagus.

OMIM : 58 Eosinophilic esophagitis (EOE) has an incidence of approximately 1 per 10,000 people. Symptoms include difficulty feeding, failure to thrive, vomiting, epigastric or chest pain, dysphagia, and food impaction. Individuals with EOE are predominantly young males with a high rate of atopic disease, and the diagnosis is made by endoscopy and biopsy findings of isolated eosinophils in the esophagus (summary by Rothenberg et al., 2010). (610247)

Wikipedia : 77 Eosinophilic esophagitis (EoE, also spelled eosinophilic oesophagitis), also known as allergic... more...

Related Diseases for Esophagitis, Eosinophilic, 1

Diseases in the Esophagitis, Eosinophilic, 1 family:

Esophagitis, Eosinophilic, 2

Diseases related to Esophagitis, Eosinophilic, 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 209)
# Related Disease Score Top Affiliating Genes
1 peptic esophagitis 30.5 ATP12A ATP4A EPC2
2 esophageal candidiasis 30.5 ATP12A ATP4A
3 ige responsiveness, atopic 30.5 IL13 IL5 STAT6
4 gastrointestinal system disease 30.3 ATP12A ATP4A CCL11
5 dyskinesia of esophagus 30.2 ATP12A ATP4A
6 pollen allergy 30.2 EPX IL13 IL5
7 esophageal disease 30.1 ATP12A ATP4A CCL26
8 gastroenteritis 29.9 CCL11 IL5 TSLP
9 rhinitis 29.9 CCL11 EPX IL13 IL5
10 allergic rhinitis 29.9 CCL11 EPX IL13 IL5
11 hypereosinophilic syndrome 29.7 CCL11 EPX IL13 IL5
12 eosinophilic gastroenteritis 29.6 CCL11 EPX IL5 TSLP
13 esophagitis 29.5 CCL11 CCL26 DSG1 IL13 IL5 TSLP
14 peanut allergy 29.3 FLG IL13
15 allergic hypersensitivity disease 29.3 CCL11 EPX IL13 IL5 TSLP
16 respiratory allergy 29.2 CCL11 IL13 IL5 STAT6 TSLP
17 food allergy 29.0 EPX FLG IL13 IL5 STAT6
18 allergic asthma 28.9 CCL11 EPX IL13 IL5 STAT6 TSLP
19 dermatitis 28.7 CCL11 DSG1 FLG IL13 IL5 TSLP
20 asthma 28.6 CCL11 CCL26 EPX FLG IL13 IL5
21 dermatitis, atopic 28.4 CCL11 EPX FLG IL13 IL5 STAT6
22 esophagitis, eosinophilic, 2 12.3
23 encephalopathy, ethylmalonic 12.0
24 eosinophilic enteropathy 11.7
25 autosomal dominant intellectual disability 30 11.2
26 extraskeletal ewing sarcoma 11.1
27 pulmonary fibrosis, idiopathic 11.1
28 cystic fibrosis 11.1
29 macs syndrome 11.1
30 coccidioidomycosis 11.1
31 hemophilia 11.1
32 stachybotrys chartarum 11.1
33 fungal esophagitis 10.4 ATP12A ATP4A
34 diclofenac allergy 10.4 ATP12A ATP4A
35 gastroduodenal crohn's disease 10.4 ATP12A ATP4A
36 neonatal candidiasis 10.4 ATP12A ATP4A
37 photoallergic dermatitis 10.4 ATP12A ATP4A
38 squamous papillomatosis 10.4 ATP12A ATP4A
39 toxic megacolon 10.4 ATP12A ATP4A
40 aspiration pneumonitis 10.4 ATP12A ATP4A
41 gastrointestinal neuroendocrine benign tumor 10.4 ATP12A ATP4A
42 gastric antral vascular ectasia 10.4 ATP12A ATP4A
43 granulomatous gastritis 10.4 ATP12A ATP4A
44 gastric neuroendocrine neoplasm 10.4 ATP12A ATP4A
45 acute laryngitis 10.4 ATP12A ATP4A
46 laryngitis 10.4 ATP12A ATP4A
47 duodenitis 10.4 ATP12A ATP4A
48 rumination disorder 10.4 ATP12A ATP4A
49 active peptic ulcer disease 10.4 ATP12A ATP4A
50 congenital disorder of deglycosylation 10.4 ATP12A ATP4A

Graphical network of the top 20 diseases related to Esophagitis, Eosinophilic, 1:

Diseases related to Esophagitis, Eosinophilic, 1

Symptoms & Phenotypes for Esophagitis, Eosinophilic, 1

Human phenotypes related to Esophagitis, Eosinophilic, 1:

60 33 (show all 15)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 dysphagia 60 33 hallmark (90%) Very frequent (99-80%) HP:0002015
2 edema 60 33 hallmark (90%) Very frequent (99-80%) HP:0000969
3 esophageal stricture 60 33 hallmark (90%) Very frequent (99-80%) HP:0002043
4 esophageal obstruction 60 33 hallmark (90%) Very frequent (99-80%) HP:0005240
5 gastroesophageal reflux 60 33 frequent (33%) Frequent (79-30%) HP:0002020
6 chest pain 60 33 frequent (33%) Frequent (79-30%) HP:0100749
7 spontaneous esophageal perforation 60 33 occasional (7.5%) Occasional (29-5%) HP:0005203
8 failure to thrive 33 HP:0001508
9 vomiting 33 HP:0002013
10 esophagitis 33 HP:0100633
11 eosinophilia 33 HP:0001880
12 esophageal stenosis 60 Frequent (79-30%)
13 epigastric pain 33 HP:0410019
14 abnormality of esophagus physiology 60 Occasional (29-5%)
15 abnormality of esophagus morphology 60 Very frequent (99-80%)

Symptoms via clinical synopsis from OMIM:

Growth Other:
failure to thrive

Abdomen Gastrointestinal:
epigastric pain
difficulty feeding
food impaction

Clinical features from OMIM:


UMLS symptoms related to Esophagitis, Eosinophilic, 1:

vomiting, epigastric pain

GenomeRNAi Phenotypes related to Esophagitis, Eosinophilic, 1 according to GeneCards Suite gene sharing:

27 (show all 27)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.83 DSG1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.83 EPX
3 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.83 EPX
4 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.83 TSLP
5 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.83 CPA4
6 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.83 EPX
7 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.83 DSG1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-127 9.83 CPA4
9 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.83 CPA4
10 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.83 EPX
11 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.83 DSG1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.83 EPX
13 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.83 EPX
14 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.83 CPA4 TSLP
15 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.83 EPX
16 Increased shRNA abundance (Z-score > 2) GR00366-A-24 9.83 CPA4
17 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.83 CPA4 DSG1 EPX TSLP
18 Increased shRNA abundance (Z-score > 2) GR00366-A-3 9.83 TSLP
19 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.83 EPX
20 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.83 CPA4 DSG1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.83 EPX
22 Increased shRNA abundance (Z-score > 2) GR00366-A-56 9.83 EPX
23 Increased shRNA abundance (Z-score > 2) GR00366-A-65 9.83 EPX
24 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.83 EPX
25 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.83 DSG1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.83 EPX
27 Increased shRNA abundance (Z-score > 2) GR00366-A-92 9.83 DSG1

Drugs & Therapeutics for Esophagitis, Eosinophilic, 1

Drugs for Esophagitis, Eosinophilic, 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 128)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Fluticasone Approved, Experimental Phase 4,Phase 3,Phase 2,Not Applicable 90566-53-3 62924
Budesonide Approved Phase 4,Phase 3,Phase 2,Not Applicable 51333-22-3 5281004 63006
Lansoprazole Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 103577-45-3 3883
Dexlansoprazole Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 138530-94-6, 103577-45-3 9578005
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
6 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
11 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
12 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Anti-Allergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Bronchodilator Agents Phase 4,Phase 3,Phase 2,Not Applicable
16 Dermatologic Agents Phase 4,Phase 3,Phase 2,Not Applicable
17 Cromolyn Sodium Phase 4
18 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Not Applicable
20 Soy Bean Phase 4,Phase 2,Phase 3,Not Applicable
21 Olive Phase 4
22 Antacids Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
23 Anti-Ulcer Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
24 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
25 Proton Pump Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
Montelukast Approved Phase 3,Phase 1,Not Applicable 158966-92-8 5281040
27 Reslizumab Approved, Investigational Phase 3,Phase 2
Esomeprazole Approved, Investigational Phase 2, Phase 3,Not Applicable 161796-78-7, 161973-10-0, 119141-88-7 9568614 4594
Histamine Approved, Investigational Phase 3 51-45-6 774
Ketotifen Approved Phase 3 34580-14-8, 34580-13-7 3827
31 Leukotriene Antagonists Phase 3,Phase 1,Not Applicable
32 Antibodies Phase 3,Phase 2,Phase 1
33 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
34 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
35 Immunoglobulins Phase 3,Phase 2,Phase 1
36 Neurotransmitter Agents Phase 3,Phase 2,Not Applicable
37 Antipruritics Phase 3,Not Applicable
38 Histamine Antagonists Phase 3
Histamine Phosphate Phase 3 51-74-1 65513
40 Histamine H1 Antagonists Phase 3
Omalizumab Approved, Investigational Phase 2,Phase 1 242138-07-4
Infliximab Approved Phase 2 170277-31-3
Benzocaine Approved, Investigational Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
tannic acid Approved Phase 2,Not Applicable 1401-55-4
45 Benralizumab Approved, Investigational Phase 1, Phase 2 1044511-01-4
Losartan Approved Phase 2 114798-26-4 3961
Angiotensin II Approved, Investigational Phase 2 11128-99-7, 68521-88-0, 4474-91-3 172198
Bethanechol Approved Phase 2 674-38-4 2370
mometasone furoate Approved, Investigational, Vet_approved Phase 2 83919-23-7
50 Caseins Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 140)
# Name Status NCT ID Phase Drugs
1 Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis Completed NCT02371941 Phase 4 oral cromolyn sodium;Placebo
2 Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis Completed NCT02019758 Phase 4 Oral Viscous Budesonide;Fluticasone MDI;Placebo slurry;Placebo inhaler
3 Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis Completed NCT01846962 Phase 4 Budesonide;Fluticasone;Oral Viscous Budesonide (OVB)
4 EoE RCT Fluticasone and Omeprazole vs Fluticasone Alone Recruiting NCT03781596 Phase 4 Fluticasone;Omeprazole;Placebo oral capsule
5 The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors Terminated NCT01404832 Phase 4 Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms
6 Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone Unknown status NCT01702701 Phase 3 Montelukast;Fluticasone
7 Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis Completed NCT00635089 Phase 3 reslizumab
8 Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis Completed NCT02434029 Phase 3 Budesonide 1mg orodispersible tablet twice daily;Placebo orodispersible tablet twice daily
9 A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved Completed NCT02605837 Phase 3 Oral Budesonide Suspension (OBS);Placebo
10 Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years Completed NCT00538434 Phase 2, Phase 3
11 Eosinophilic Esophagitis Intervention Trial-1 Food vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids Completed NCT02610816 Phase 2, Phase 3 Fluticasone Propionate, 800 mcg twice daily (post 4FED failure)
12 A Study Comparing Swallowed Flovent and Placebo in Patients With Eosinophilic Disorders Completed NCT00266578 Phase 3 Fluticasone Propionate
13 The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis Completed NCT00728481 Phase 2, Phase 3 Esomeprazole;Budesonide
14 Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE) Recruiting NCT03245840 Phase 3 Budesonide oral suspension
15 Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE) Recruiting NCT03633617 Phase 3 Dupilumab;Placebo
16 SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study Recruiting NCT02778867 Phase 2, Phase 3 Flovent
17 Ketotifen for Children With Functional Dyspepsia in Association With Duodenal Eosinophilia Recruiting NCT02484248 Phase 3 Ketotifen;Placebo
18 Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis Active, not recruiting NCT02493335 Phase 3 Budesonide 0.5mg orodispersible tablet twice daily;Budesonide 1mg orodispersible tablet twice daily;Placebo orodispersible tablet twice daily
19 An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE) Active, not recruiting NCT02736409 Phase 3 Oral Budesonide Suspension (OBS);Placebo
20 Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis Completed NCT00762073 Phase 2 budesonide;placebo
21 Milk Patch for Eosinophilic Esophagitis Completed NCT02579876 Phase 2 Viaskin Milk 500 mcg;Viaskin Placebo
22 A Study of Flovent in Patients With Eosinophilic Esophagitis Completed NCT00426283 Phase 2 Flovent
23 Budesonide for Eosinophilic Esophagitis Completed NCT00271349 Phase 2 Budesonide
24 Topical Steroid Treatment for Eosinophilic Esophagitis Completed NCT00275561 Phase 2 Fluticasone;Placebo
25 Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis Completed NCT02280616 Phase 2 low dose budesonide tablet;high dose budesonide tablet;high dose budesonide suspension;Placebo
26 Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis Completed NCT02098473 Phase 2 RPC4046;Placebo
27 Proof of Concept Study of OC000459 in Eosinophilic Esophagitis Completed NCT01056783 Phase 2 OC000459;Placebo
28 Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis Completed NCT01386112 Phase 1, Phase 2 EUR-1100;placebo
29 Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis Completed NCT00638456 Phase 2 Budesonide plus Prevacid;placebo plus Prevacid
30 Study of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis (EoE) Completed NCT02379052 Phase 2 Dupilumab;Placebo
31 Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis Completed NCT01022970 Phase 2 QAX576 placebo;QAX576
32 A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab Completed NCT00123630 Phase 2 omalizumab;Placebo
33 OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension Completed NCT01642212 Phase 2 Oral Budesonide Suspension (MB-9);Placebo
34 Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis Completed NCT00123656 Phase 2 esomeprazole;fluticasone
35 Off Label Use of Infliximab in Adult Patients With Severe Eosinophilic Esophagitis Completed NCT00523354 Phase 2 Infliximab
36 Intravenous Mepolizumab In Children With Eosinophilic Esophagitis Completed NCT00358449 Phase 2 mepolizumab
37 An Evaluation Of Mepolizumab In Therapy Of Eosinophilic Oesophagitis In Adult Patients Completed NCT00274703 Phase 2 mepolizumab
38 Omalizumab to Treat Eosinophilic Gastroenteritis Completed NCT00084097 Phase 2 Omalizumab
39 Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome Completed NCT00017862 Phase 2 SCH55700
40 Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome Completed NCT00266565 Phase 1, Phase 2 Mepolizumab
41 Benralizumab for Eosinophilic Gastritis Recruiting NCT03473977 Phase 1, Phase 2
42 Mepo for EoE Study Recruiting NCT03656380 Phase 2 Mepolizumab 300 mg;Mepolizumab 100 mg
43 A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis Recruiting NCT03496571 Phase 2 AK002
44 Eosinophilic Esophagitis Clinical Therapy Comparison Trial Active, not recruiting NCT01821898 Phase 2 Oral Budesonide
45 Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE) Active, not recruiting NCT03191864 Phase 2 APT-1011;Placebo
46 An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) Active, not recruiting NCT03029091 Phase 2 Losartan Potassium
47 Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD Active, not recruiting NCT01808196 Phase 2 Losartan Potassium
48 An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis Enrolling by invitation NCT03664960 Phase 2 AK002
49 Efficacy and Safety of Three Doses of Florence Oral Suspension in Adults With Eosinophilic Esophagitis Not yet recruiting NCT02873468 Phase 2 Florence 30 μg/mL;Florence 60 μg/mL;Florence 90 μg/mL
50 DEGS - Dupilumab for Eosinophilic Gastritis Study Not yet recruiting NCT03678545 Phase 2 Dupilumab (blinded);Placebo (blinded);Dupilumab (open-label)

Search NIH Clinical Center for Esophagitis, Eosinophilic, 1

Cochrane evidence based reviews: eosinophilic esophagitis

Genetic Tests for Esophagitis, Eosinophilic, 1

Anatomical Context for Esophagitis, Eosinophilic, 1

MalaCards organs/tissues related to Esophagitis, Eosinophilic, 1:

Testes, Skin, Bone, T Cells, Kidney, Smooth Muscle, Lymph Node

The Foundational Model of Anatomy Ontology organs/tissues related to Esophagitis, Eosinophilic, 1:


Publications for Esophagitis, Eosinophilic, 1

Articles related to Esophagitis, Eosinophilic, 1:

(show top 50) (show all 1551)
# Title Authors Year
Plasma levels of TNF-α, IL-6, IFN-γ, IL-12, IL-17, IL-22, and IL-23 in achalasia, eosinophilic esophagitis (EoE), and gastroesophageal reflux disease (GERD). ( 30744559 )
Eosinophilic esophagitis and achalasia - just a coincidence? ( 30754060 )
Eosinophilic esophagitis, gastroenteritis, and colitis in a patient with prior parasite exposure. ( 31077082 )
Prevalence of Eosinophilic Esophagitis in Adolescents with Esophageal Atresia. ( 30614952 )
Is There a Role for pH Impedance Monitoring in Identifying Eosinophilic Esophagitis in Children with Esophageal Atresia? ( 31036410 )
New Developments in the Diagnosis and Treatment of Eosinophilic Esophagitis. ( 30707411 )
Transnasal Endoscopy in Unsedated Children With Eosinophilic Esophagitis Using Virtual Reality Video Goggles. ( 30708107 )
A conceptual approach to understanding treatment response in eosinophilic esophagitis. ( 30710696 )
A Comparative Analysis of Eating Behavior of School-Aged Children with Eosinophilic Esophagitis and Their Caregivers' Quality of Life: Perspectives of Caregivers. ( 30712065 )
Management of eosinophilic esophagitis is often discordant with guidelines and not patient-centered: results of a survey of gastroenterologists. ( 30715230 )
Screening children for eosinophilic esophagitis: allergic and other risk factors. ( 30722709 )
Assessing the Risk Factors for Refractory Eosinophilic Esophagitis in Children and Adults. ( 30755767 )
Eosinophilic Esophagitis-A Primer for Otolaryngologists. ( 30789641 )
Molecular basis and cellular mechanisms of eosinophilic esophagitis for the clinical practice. ( 30791784 )
Eosinophilic esophagitis: Pathophysiology, diagnosis, and management. ( 30827775 )
Subcutaneous immunotherapy in patients with eosinophilic esophagitis. ( 30831258 )
Food impaction: etiology over 35 years and association with eosinophilic esophagitis. ( 30847465 )
Eosinophilic esophagitis after total gastrectomy treated with proton pump inhibitors: a case report. ( 30848447 )
Penetration of the Esophageal Epithelium by Dust Mite Antigen in Patients With Eosinophilic Esophagitis. ( 30849319 )
Mediastinal abscess, an unusual way of presentation of eosinophilic esophagitis. ( 30858868 )
Efficacy of Budesonide vs Fluticasone for Initial Treatment of Eosinophilic Esophagitis in a Randomized Controlled Trial. ( 30872104 )
Sustained Remission of Eosinophilic Esophagitis Following Discontinuation of Dietary Elimination in Children. ( 30880275 )
Diagnosis of Eosinophilic Esophagitis in Children - A Serbian Single Center Experience from 2010 to 2017. ( 30884488 )
Combination Therapy with Elimination Diet and Corticosteroids is Effective for Adults with Eosinophilic Esophagitis. ( 30885887 )
Avoidant/Restrictive Food Intake Disorder in Diet-Treated Children with Eosinophilic Esophagitis. ( 30889128 )
Eosinophilic esophagitis after an episode of herpetic esophagitis. ( 30896955 )
Allergic Comorbidity in Eosinophilic Esophagitis: Mechanistic Relevance and Clinical Implications. ( 30903437 )
Mobile health tool detects adherence rates in pediatric patients with eosinophilic esophagitis. ( 30910711 )
Sensitivity and Specificity of Administrative Medical Coding for Pediatric Eosinophilic Esophagitis. ( 30921258 )
Pediatric Celiac Disease and Eosinophilic Esophagitis: Outcome of Dietary Therapy. ( 30921260 )
Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-controlled Trial. ( 30922997 )
Illuminating Elimination Diets: Controversies Regarding Dietary Treatment of Eosinophilic Esophagitis. ( 30927211 )
Food Allergy, Eosinophilic Esophagitis and the Enigma of IgG4. ( 30928417 )
Association between endoscopic findings of eosinophilic esophagitis and responsiveness to proton pump inhibitors. ( 30931374 )
Serum eosinophilic cationic protein is correlated with food impaction and endoscopic severity in eosinophilic esophagitis. ( 30945644 )
Single-cell RNA sequencing identifies inflammatory tissue T cells in eosinophilic esophagitis. ( 30958799 )
Singling out Th2 cells in eosinophilic esophagitis. ( 30958801 )
Eosinophilic Esophagitis. ( 30964530 )
Occupational Allergic Respiratory Disease and Eosinophilic Esophagitis by Wheat Flour in a Baker. ( 30982690 )
Involvement of EP2 and EP4 Receptors in Eosinophilic Esophagitis: A Pilot Study. ( 30989466 )
Development and Application of a Functional Human Esophageal Mucosa Explant Platform to Eosinophilic Esophagitis. ( 30996235 )
Correction to: Eosinophilic esophagitis. ( 31007687 )
Cost-effective care in eosinophilic esophagitis. ( 31009702 )
Gastroesophageal Reflux Disease and Eosinophilic Esophagitis. ( 31011306 )
Esophageal dilation in eosinophilic esophagitis using a novel endoscopic device. ( 31014940 )
Eosinophilic Esophagitis: Personalized Treatment With an Elimination Diet Based on IgE Levels in Children Aged <16 Years. ( 31017120 )
Pearls and pitfalls in the management of eosinophilic esophagitis. ( 31018896 )
Developing Pharmacologic Treatments for Eosinophilic Esophagitis: Draft Guidance from the United States Food and Drug Administration. ( 31022402 )
Bagels and LOX in Eosinophilic Esophagitis. ( 31051184 )
Acute intramucosal dissection in eosinophilic esophagitis. ( 31054020 )

Variations for Esophagitis, Eosinophilic, 1

Expression for Esophagitis, Eosinophilic, 1

Search GEO for disease gene expression data for Esophagitis, Eosinophilic, 1.

Pathways for Esophagitis, Eosinophilic, 1

GO Terms for Esophagitis, Eosinophilic, 1

Cellular components related to Esophagitis, Eosinophilic, 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 CCL11 CCL26 CPA4 EPX IL13 IL5
2 extracellular space GO:0005615 9.28 ATP4A CCL11 CCL26 CPA4 EPX IL13

Biological processes related to Esophagitis, Eosinophilic, 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.73 CCL11 CCL26 IL13 IL5
2 cellular response to tumor necrosis factor GO:0071356 9.58 CCL11 CCL26 POSTN
3 cytokine-mediated signaling pathway GO:0019221 9.56 CCL11 IL13 IL5 STAT6
4 eosinophil chemotaxis GO:0048245 9.46 CCL11 CCL26
5 cellular sodium ion homeostasis GO:0006883 9.37 ATP12A ATP4A
6 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.32 ATP12A ATP4A
7 cellular potassium ion homeostasis GO:0030007 9.16 ATP12A ATP4A
8 regulation of signaling receptor activity GO:0010469 9.02 CCL11 CCL26 IL13 IL5 TSLP
9 sodium ion export across plasma membrane GO:0036376 8.96 ATP12A ATP4A

Molecular functions related to Esophagitis, Eosinophilic, 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sodium:potassium-exchanging ATPase activity GO:0005391 9.26 ATP12A ATP4A
2 CCR3 chemokine receptor binding GO:0031728 9.16 CCL11 CCL26
3 cytokine activity GO:0005125 9.02 CCL11 CCL26 IL13 IL5 TSLP
4 potassium:proton exchanging ATPase activity GO:0008900 8.96 ATP12A ATP4A

Sources for Esophagitis, Eosinophilic, 1

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
33 HPO
34 ICD10
35 ICD10 via Orphanet
39 LifeMap
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
56 Novoseek
59 OMIM via Orphanet
63 PubMed
71 SNOMED-CT via Orphanet
73 Tocris
75 UMLS via Orphanet
Loading form....